Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
View Patent ↗The invention relates to pharmaceutical administration forms with sustained release comprising at least one pharmacologically active peptide. The invention also relates to a method for the production thereof, a kit comprising a lyophilised peptide and an aqueous solution of an inorganic salt or acetic acid salt and the use of an aqueous solution of an inorganic or acetic acid salt for producing a pharmaceutical administration form which releases peptides in a continuous manner over a long period of time.
1. A pharmaceutical gel preparation comprising a mixture of:
(a) D-63153 or a pharmaceutically active salt thereof in lyophilized form at a concentration of from 5 to 50 mg of peptide per ml of the preparation, and
(b) an aqueous solution of sodium chloride at a concentration of from 0.05% to 0.2% (weight/volume), and
wherein the preparation is suitable for administration after reconstitution of (a) by the mixing of (a) and (b) and after a standing time of up to about 120 minutes subsequent to the mixing of (a) and (b).
2. The pharmaceutical preparation as claimed in claim 1 wherein the pharmaceutical gel preparation further comprises at least one pharmaceutically active ionic peptide compound selected from the group consisting of cetrorelix, teverelix, abarelix, ganirelix, azaline B, antide, detirelix, ramorelix, degarelix, or their pharmaceutically active salt and mixtures thereof.
3. The pharmaceutical preparation as claimed in claim 1 wherein D-63153 is a pharmaceutically active salt.
4. The pharmaceutical preparation as claimed in claim 1 wherein said aqueous solution further comprises an aqueous inorganic salt or acetic acid salt selected from the group consisting of calcium chloride, magnesium chloride, sodium acetate, calcium acetate, magnesium acetate and mixtures thereof.
5. The pharmaceutical preparation as claimed in claim 1 wherein the mixture is a liquid suspension or a semisolid dispersion.
6. The pharmaceutical preparation as claimed in claim 1 wherein the concentration of D-63153 is in the range from about 10 to about 50 mg per ml of the total amount of the pharmaceutical preparation.
7. The pharmaceutical preparation as claimed in claim 1 wherein the concentration of D-63153 is in the range from about 20 to about 30 mg per ml of the total amount of the pharmaceutical preparation.
8. The pharmaceutical preparation as claimed in claim 1 wherein the concentration of D-63153 is in the region of about 25 mg per ml of the total amount of the pharmaceutical preparation.
9. The pharmaceutical preparation as claimed in claim 1 wherein the concentration of sodium chloride ranges from 0.1% to 0.2% (weight/volume).
10. The pharmaceutical preparation as claimed in claim 1 wherein the concentration of sodium chloride is about 0.1% (weight/volume).
11. The pharmaceutical preparation as claimed in claim 1 wherein the concentration of D-63153 is about 25 mg per ml of the preparation, and the concentration of sodium chloride is about 0.1% (weight/volume).
12. A method for producing a pharmaceutical gel preparation as claimed in claim 1 comprising
A) bringing together said D-63153 in lyophilized form and said aqueous solution and
B) mixing the components.
13. The method for producing a pharmaceutical preparation as claimed in claim 12 , wherein the concentration of D-63153 is about 25 mg/ml, and the concentration of sodium chloride is about 0.1% (weight/volume).
14. The method for producing a pharmaceutical preparation as claimed in claim 12 , further comprising sterilizing the peptide formulation by irradiation with gamma rays or electron beams.
15. The method for producing a pharmaceutical preparation as claimed in claim 12 , where the production of (a) takes place with use of aseptic procedures.
16. A kit for producing a pharmaceutical gel preparation as claimed in claim 1 , comprising from 5 to 50 mg per ml of the finished preparation of D-63153 in lyophilized form and an aqueous solution of an inorganic or acetic acid salt at a concentration of from 0.05% to 0.2% (weight/volume).
17. The kit as claimed in claim 16 , wherein the D-63153 lyophilizate additionally comprises mannitol.
18. The kit as claimed in claim 16 wherein the concentration of D-63153 is about 25 mg per finished preparation and the concentration of the aqueous sodium chloride solution is about 0.1% weight/volume.
19. A method for treating a patient with D-63153, wherein a pharmaceutical preparation as claimed in claim 1 is administered subcutaneously or intramuscularly to the patient.
20. The method as claimed in claim 19 wherein the administered pharmaceutical preparation displays a sustained pharmaceutical activity.
21. The method as claimed in claim 19 wherein the administered pharmaceutical preparation displays a sustained pharmaceutical activity for at least 4 weeks.
22. The method as claimed in claim 19 wherein the administered pharmaceutical preparation displays a sustained pharmaceutical activity for at least 8 weeks.
23. The method as claimed in claim 19 wherein the administered pharmaceutical preparation displays a sustained pharmaceutical activity for at least 12 weeks.
24. A method for treating a hormone-dependent disorder in a patient by subcutaneous or intramuscular administration of a pharmaceutical preparation as claimed in claim 1 in a patient need thereof.
25. A method for treating prostate cancer in a patient by subcutaneous or intramuscular administration of a pharmaceutical preparation as claimed in claim 1 in a patient need thereof.
26. A method for treating breast cancer in a patient by subcutaneous or intramuscular administration of a pharmaceutical preparation as claimed in claim 1 in a patient need thereof.
27. A method for treating uterine myomas in a patient by subcutaneous or intramuscular administration of a pharmaceutical preparation as claimed in claim 1 in a patient need thereof.
28. A method for treating endometriosis in a patient by subcutaneous or intramuscular administration of a pharmaceutical preparation as claimed in claim 1 in a patient need thereof.
29. A method for treating precocious puberty in a patient by subcutaneous or intramuscular administration of a pharmaceutical preparation as claimed in claim 1 in a patient need thereof.
30. A method for modifying the reproductive function in a patient by subcutaneous or intramuscular administration of a pharmaceutical preparation as claimed in claim 1 in a patient need thereof.
31. The pharmaceutical preparation as claimed in claim 1 wherein the mixture is a molecular-dispersed or colloidal mixture which may be of liquid to semisolid consistency.
32. The pharmaceutical preparation as claimed in claim 1 wherein a colloidal dispersion is formed by reconstitution.
33. The pharmaceutical preparation as claimed in claim 1 wherein a colloidal dispersion is formed by storage or leaving to stand after reconstitution and changes its viscosity as a function of time and thus improves the reproducibility of the delayed release of active ingredient.